Mutations accumulated in the Spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin

PLoS Pathog. 2024 Jan 8;20(1):e1011912. doi: 10.1371/journal.ppat.1011912. eCollection 2024 Jan.

Abstract

BST2/Tetherin is a restriction factor with broad antiviral activity against enveloped viruses, including coronaviruses. Specifically, BST2 traps nascent particles to membrane compartments, preventing their release and spread. In turn, viruses have evolved multiple mechanisms to counteract BST2. Here, we examined the interactions between BST2 and SARS-CoV-2. Our study shows that BST2 reduces SARS-CoV-2 virion release. However, the virus uses the Spike (S) protein to downregulate BST2. This requires a physical interaction between S and BST2, which routes BST2 for lysosomal degradation in a Clathtin- and ubiquitination-dependent manner. By surveying different SARS-CoV-2 variants of concern (Alpha-Omicron), we found that Omicron is more efficient at counteracting BST2, and that mutations in S account for its enhanced anti-BST2 activity. Mapping analyses revealed that several surfaces in the extracellular region of BST2 are required for an interaction with the Spike, and that the Omicron variant has changed its patterns of association with BST2 to improve its counteraction. Therefore, our study suggests that, besides enhancing receptor binding and evasion of neutralizing antibodies, mutations accumulated in the Spike afford more efficient counteraction of BST2, which highlights that BST2 antagonism is important for SARS-CoV-2 infectivity and spread.

MeSH terms

  • Bone Marrow Stromal Antigen 2*
  • COVID-19* / genetics
  • GPI-Linked Proteins / genetics
  • GPI-Linked Proteins / metabolism
  • Humans
  • Mutation
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / metabolism
  • Spike Glycoprotein, Coronavirus / genetics

Substances

  • Bone Marrow Stromal Antigen 2
  • GPI-Linked Proteins
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • BST2 protein, human

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

These studies have been funded through a University of Rochester Research Award to RSM (OP212320) and an Empire State Development NYFirst to RSM (# 134,351). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.